Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease
Miki Imazu(National Cerebral and Cardiovascular Center), Masafumi Kitakaze(Hanwa Memorial Hospital), Akira Funada(National Cerebral and Cardiovascular Center), Hiroshi Asanuma(Meiji University of Integrative Medicine), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Hiroyuki Takahama(Tohoku University), Masanori Asakura(National Cerebral and Cardiovascular Center), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Takahiro Ohara(Tohoku Medical and Pharmaceutical University), Toshihisa Anzai(Hokkaido University), Yasuo Sugano(keiyu Hospital)
American Journal of Physiology-Heart and Circulatory Physiology
September 13, 2014
Cited by 44
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
Right Ventricular Function in Heart Failure With Preserved Ejection Fraction
|Circulation|2014|456